Clinical Trials
960
300 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1614
Active, not recruiting
157
16.4%
Completed
334
34.8%
Enrolling By Invitation
9
0.9%
Not yet recruiting
134
14.0%
Recruiting
198
20.6%
Suspended
2
0.2%
Terminated
30
3.1%
Unknown
87
9.1%
Withdrawn
9
0.9%
No approval data available
- The Molecular Imaging World Summit 2026 in Copenhagen highlighted long axial field-of-view (LAFOV) PET/CT scanners as transformative for whole-body perfusion imaging and systemic disease evaluation across cancer, cardiovascular, and neurodegenerative conditions. - ImmunoPET with LAFOV scanners unlocks unprecedented opportunities for personalized cancer therapies by targeting both tumor antigens and immune cells, according to Dr. Erik Aarntzen of University Medical Center Groningen. - PET/MRI is emerging as the platform of choice for neuromolecular imaging, enabling simultaneous acquisition of molecular and multiparametric structural data with significantly reduced radiation exposure. - Global access to theranostics is expanding through innovative financing models, strategic partnerships, and flexible delivery pathways, with programs demonstrating success in both industrialized and resource-limited settings.
- Rectify Pharmaceuticals presented new preclinical data at EASL 2026 showing RTY-406 significantly improved disease-relevant endpoints in a mouse model of primary sclerosing cholangitis and demonstrated proof of mechanism in non-human primates. - RTY-406 is a dual-acting ABCB4/BSEP positive functional modulator that targets abnormal bile composition and impaired bile flow, two core pathophysiological drivers of PSC. - The drug candidate is currently in Phase 1 clinical development as a potential first-in-class disease-modifying therapy for PSC patients, a devastating disease with no approved therapies addressing underlying biology. - In preclinical studies, RTY-406 reduced markers of cholestasis, fibrosis, and inflammation while demonstrating dose-dependent improvements in liver function markers without evidence of liver toxicity.
- QT Sense raised €4 million to accelerate development of Quantum Nuova, a quantum-sensing platform that uses fluorescent nanodiamond sensors to monitor cellular processes in real-time. - The platform enables researchers to observe oxidative stress, metabolic shifts, and free radical kinetics at single-cell resolution in living cells, unlike traditional methods requiring fixed tissue samples. - The technology has already characterized mechanism-of-action for several FDA-approved drugs and will focus on colorectal cancer research under the ONCO-Q grant. - The funding will support transitioning the prototype into a deployable discovery platform for drug development and clinical research applications.
- DEBRA Research gGmbH and the University Medical Center Groningen have established a dedicated clinical trial site for Epidermolysis bullosa (EB), strengthening research infrastructure for this rare genetic skin disorder. - The collaboration will enhance clinical trial capacity in a region with recognized expertise in EB diagnosis and care, led by Principal Investigator Dr. Marieke C. Bolling. - DEBRA Research is supporting the international COSEB project to standardize outcome measurements across EB studies, ensuring future trials generate robust and comparable data. - The partnership aims to accelerate therapeutic innovation for the global EB community by improving trial efficiency and supporting both company-sponsored and investigator-initiated studies.
- Mendus AB announced positive 2-year follow-up data from the ALISON Phase 1 trial, confirming safety, tolerability and feasibility of vididencel as an active immunotherapy in high-risk ovarian cancer. - Out of 17 patients treated, 8 patients remain alive after 2-year follow-up, with improved tumor-directed immune responses associated with better survival outcomes. - The trial demonstrated no product-related serious side effects, positioning vididencel for potential combination therapies with PARP inhibitors, immune checkpoint inhibitors and T cell engagers. - Stable disease was observed in 42% of patients with tumor-directed immune responses compared to 20% without such responses, including 2 patients maintaining stability beyond 3.5 years.
- A Phase 3 clinical trial demonstrated that finerenone (Kerendia) reduced protein loss in urine by approximately 25% in 242 type 1 diabetes patients with chronic kidney disease over six months. - The study represents the first effective and safe drug breakthrough for type 1 diabetes kidney complications in more than three decades, addressing a critical unmet medical need. - Finerenone works by blocking aldosterone receptors and was well-tolerated except for slightly elevated blood potassium levels, offering hope for the 30-40% of type 1 diabetes patients who develop chronic kidney disease.
- Children participating in team sports like soccer and volleyball demonstrate superior executive function skills compared to those in individual sports or no sports, according to a Dutch longitudinal study published in JAMA Network Open. - Structured sports participation increases high school graduation rates, with boys showing a 15% higher likelihood and girls a 7% higher likelihood of obtaining diplomas by age 20, research from the University of Montreal reveals. - Girls engaged in organized and artistic sports achieved 8% and 23% higher grades respectively, highlighting the significant cognitive and academic benefits of team-based physical activities.
- Post hoc analysis of SURPASS trials reveals tirzepatide significantly reduced urine albumin-to-creatinine ratio by up to 26.3% compared to control groups in type 2 diabetes patients. - Patients with chronic kidney disease showed even more pronounced benefits, with the highest tirzepatide dose (15mg) achieving up to 49.2% greater reduction in albuminuria compared to comparators. - The study demonstrates tirzepatide's dual mechanism of action, with 54.1% of albuminuria reduction attributed to direct effects and 45.9% to improvements in HbA1c and body weight.
- Brexucabtagene autoleucel (brexu-cel) shows a 91% overall response rate (ORR) in patients with relapsed/refractory mantle cell lymphoma (MCL) who are BTK inhibitor-naive. - The ZUMA-2 trial's cohort 3 reveals a 73% complete response rate with brexu-cel, suggesting its potential as an earlier-line treatment for high-risk MCL. - High ORRs were observed across various high-risk subgroups, including those with TP53 mutations and high Ki-67 scores, indicating broad efficacy. - The safety profile of brexu-cel in BTK inhibitor-naive patients was consistent with previous findings, with manageable rates of cytokine release syndrome and neurotoxicity.
- Semaglutide, the active agent in Ozempic and Wegovy, demonstrates a significant 52% reduction in kidney damage among obese individuals without diabetes. - The study also revealed a 30% reduction in kidney inflammation in patients treated with semaglutide over a 24-week period. - Participants taking semaglutide experienced approximately 10% weight loss and a decrease in high blood pressure, similar to that achieved with blood pressure medication. - Researchers aim to investigate semaglutide's potential to reduce the need for dialysis or kidney transplants and its efficacy in non-obese patients with kidney damage.
